Multi-Ethnic Analysis of Cardiac Pharmacogenetic Markers of Cytochrome P450 and Membrane Transporters Genes in the Russian Population
Open Access
- 6 July 2019
- journal article
- research article
- Published by Silicea - Poligraf in Rational Pharmacotherapy in Cardiology
- Vol. 15 (3), 393-406-406
- https://doi.org/10.20996/1819-6446-2019-15-3-393-406
Abstract
Aim. To summarize Russian studies using pharmacogenetic testing as applied to cardiology. Material and methods. The authors conducted an online search for articles in December 2018 using the following databases: PubMed, Google Scholar, eLIBRARY. The search was carried out by keywords: "Russia", "Russian", "cardiology" together with the terms associated with the polymorphic marker, including: «P450», «CYP2C19», «CYP2D6», «CYP2B1», «CYP2B6», «CYP2Е1», «CYP2C8», «CYP2C9», «CYP3A4», «CYP3A5», «CYP1A1», «CYP1A2», «CYP4F2», «CYP4F1», «ABCB1», «SLCO1B1», «VKORC1», «GGCX», «SULT1A1», «CULT1», «CES1», «gene», «genes», «pharmacogenetics», «pharmacogenomics», «ethnic group». Results. Generalization of information allowed to identify obscure genes that need to be investigated in pharmacogenetic studies. This information can be used for the development of dosing algorithms and the priority choice of drugs, considering the results of pharmacogenetic testing and planning future research. Conclusion. The results of the literature review indicate the importance of studying the most clinically valid and clinically useful pharmacogenetic markers (CYP2C19, CYP2C9, VKORC1, SLCO1B1) among various ethnic groups in the Russian Federation. With the accumulation of evidence of clinical validity and clinical utility of other pharmacogenetic markers (CES1, CYP2D6*4, etc.), the problem of interethnic differences in the carriage of clinically significant polymorphisms of these genes identified in previous studies in the Russian Federation increasingly requires attention. The most promising for the introduction into the clinical practice in the Russian Federation in the near future are polymorphic markers of the CYP2C19, CYP2C9, VKORC1 and SLCO1B1 genes.Keywords
This publication has 63 references indexed in Scilit:
- Microarray-Based Detection ofCYP1A1,CYP2C9,CYP2C19,CYP2D6,GSTT1,GSTM1,MTHFR,MTRR,NQO1,NAT2,HLA-DQA1, andAB0Allele Frequencies in Native RussiansGenetic Testing and Molecular Biomarkers, 2010
- Genetic variation of genes for xenobiotic-metabolizing enzymes and risk of bronchial asthma: the importance of gene–gene and gene–environment interactions for disease susceptibilityJournal of Human Genetics, 2009
- Cytochrome P450 2D6Pharmacogenetics and Genomics, 2009
- A synonymous polymorphism in a common MDR1 (ABCB1) haplotype shapes protein functionBiochimica et Biophysica Acta (BBA) - Proteins and Proteomics, 2009
- A Multifaceted Approach to SafetyJournal of Patient Safety, 2008
- SLCO1B1Variants and Statin-Induced Myopathy — A Genomewide StudyThe New England Journal of Medicine, 2008
- Polymorphisms in xenobiotic‐metabolizing genes and the risk of chronic lymphocytic leukemia and non‐Hodgkin's lymphoma in adult Russian patientsAmerican Journal of Hematology, 2007
- Drug–drug interactions affected by the transporter protein, P-glycoprotein (ABCB1, MDR1): II. Clinical aspectsDrug Discovery Today, 2007
- Association of CYP2D6 and ADRB1 genes with hypotensive and antichronotropic action of betaxolol in patients with arterial hypertensionFundamental & Clinical Pharmacology, 2007
- A common novel CYP2C19 gene variant causes ultrarapid drug metabolism relevant for the drug response to proton pump inhibitors and antidepressantsClinical Pharmacology & Therapeutics, 2006